Biogen Idec (BIIB) Upgraded by William Blair to "Outperform" LocalizedUSA It includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1a. Shares of Biogen Idec traded down 1.07% during mid-day trading on Monday, hitting $92.15. ... |
